Favorable prognosis of chronic hepatitis C after interferon therapy by long‐term cohort study

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Hepatology

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/JHEP.2003.50329PMID 12883494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon therapy prolonged life expectancy among chronic hepatitis C patients.

  2002cited by this paper
• Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis

  2001cited by this paper
• Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.

  2001cited by this paper
• Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: A retrospective cohort study of 738 patients

  2000cited by this paper
• Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy

  2000cited by this paper
• A Dose‐Ranging Study of Pegylated Interferon Alfa‐2b and Ribavirin in Chronic Hepatitis C

  2000cited by this paper
• A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

  1999cited by this paper
• Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

  1999cited by this paper
• Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis

  1999influential reference
• Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa‐2b versus no treatment

  1999cited by this paper
• Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis

  1998cited by this paper
• Determinants of outcome of compensated hepatitis C virus‐related cirrhosis

  1998cited by this paper
• Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

  1998cited by this paper
• Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

  1998cited by this paper
• Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.

  1997cited by this paper
• Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).

  1997cited by this paper
• Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.

  1997cited by this paper
• Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: A meta‐analysis of diagnostic test characteristics

  1997cited by this paper
• Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

  1996cited by this paper
• Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa

  1996cited by this paper
• Clinical outcomes after transfusion-associated hepatitis C.

  1995influential reference
• Characteristic difference of hepatocellular carcinoma between hepatitis B‐ and C‐ viral infection in Japan

  1995cited by this paper
• Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

  1995cited by this paper
• Classification of chronic hepatitis: Diagnosis, grading and staging

  1994cited by this paper
• Significance of specific antibody assay for genotyping of hepatitis C virus

  1994cited by this paper
• High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon‐α2b for 60 weeks

  1994cited by this paper
• Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy.

  1993cited by this paper
• Quantification of hepatitis C virus by competitive reverse transcription—polymerase chain reaction: Increase of the virus in advanced liver disease

  1993cited by this paper
• Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

  1993cited by this paper
• Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C.

  1991cited by this paper
• Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

  1989cited by this paper
• Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

  1989cited by this paper
• Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis.

  1989influential reference
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

  2020cites this paper
• Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle‐aged patients with non‐alcoholic fatty liver disease

  2019cites this paper
• Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis

  2017cites this paper
• Hepatitis Viruses and Hepatoma

  2017cites this paper
• Long-term follow-up of patients with chronic hepatitis C treated with &agr;-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response

  2017cites this paper
• Why is Viral Eradication so Important in Patients with HCV-Related Cirrhosis?

  2016cites this paper
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

  2016cites this paper
• Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010

  2016cites this paper
• Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response

  2015cites this paper
• Viral hepatitis and HIV co-infection in the UK Collaborative HIV cohort (UK CHIC) study

  2015cites this paper
• Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

  2015influential citation
• Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response

  2015cites this paper
• Hepatitis C virus-associated cancer.

  2015cites this paper
• Assessment of Predictors for Early Resistance to Hepatitis C Virus Treatment

  2015cites this paper
• HCV and HIV co-infection: mechanisms and management

  2014cites this paper
• Hepatocellular carcinoma in patients with chronic hepatitis C: Experience gained at Clinical Center of Vojvodina

  2014cites this paper
• Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease

  2014cites this paper
• Reduced Organic Anion Transporter Expression Is a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients: A Propensity Score Matching Study

  2014cites this paper
• Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study

  2013cites this paper
• Virological response for recurrent hepatitis C improves long‐term survival in liver transplant recipients

  2013cites this paper
• Sustained and rapid virological responses in hepatitis C clinical trials

  2013cites this paper
• Is Sustained Virological Response a Marker of Treatment Efficacy in Patients with Chronic Hepatitis C Viral Infection with No Response or Relapse to Previous Antiviral Intervention?

  2013cites this paper
• Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.

  2013cites this paper
• The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial.

  2013cites this paper
• Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review

  2013cites this paper
• Sustained virological response: a milestone in the treatment of chronic hepatitis C.

  2013cites this paper
• The natural history and long‐term outcomes in patients with chronic hepatitis C genotype 4 after interferon‐based therapy

  2013cites this paper
• Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C

  2013cites this paper
• HEPATITIS C VIRUS

  2012cites this paper
• iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns

  2012cites this paper
• HEPATITIS C VIRUS The hepatitis C virus was considered by a previous

  2012cites this paper
• Effectiveness of biweekly low‐dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α‐fetoprotein levels

  2012cites this paper
• Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.

  2012cites this paper
• Multicentric hepatocarcinogenesis at 6 and 13 years after sustained viral response to hepatitis C virus

  2012cites this paper
• Touching some firm ground in the epidemiology of NASH.

  2012cites this paper
• Psychiatric Side Effects and Fluctuations in Serotonergic Parameters in the Treatment of Chronic Hepatitis C Infection

  2012cites this paper
• Neuropsychiatric and other side effects of peginterferon-based therapy of chronic hepatitis C infection

  2012cites this paper
• Hepatitis C Virus Treatment in HIV

  2012cites this paper
• Treatment for Hepatitis C Virus Infection in Adults

  2012cites this paper
• Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study

  2012cites this paper
• Long-term outcomes of chronic hepatitis C patients treated with pegylated interferon 2a plus ribavirin in Iran

  2012cites this paper
• Basic answers to complicated questions for the course of chronic hepatitis C treatment

  2012cites this paper
• Occurrence of Hepatocellular Carcinoma Was Not a Rare Event during and Immediately after Antiviral Treatment in Japanese HCV-Positive Patients

  2011cites this paper
• Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection

  2011cites this paper
• Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma.

  2011cites this paper
• Peginterferon and ribavirin treatment for hepatitis C virus infection.

  2011cites this paper
• Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.

  2011influential citation
• ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C

  2011cites this paper
• A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

  2011cites this paper
• Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

  2011cites this paper
• Outcome of sustained virological responders with histologically advanced chronic hepatitis C

  2010cites this paper
• Individualisation of antiviral therapy for chronic hepatitis C

  2010cites this paper
• Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C

  2010cites this paper
• Health care costs associated with hepatitis C: a longitudinal cohort study.

  2010cites this paper
• Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development.

  2010cites this paper
• Hepatitis C virus-induced hepatocarcinogenesis.

  2009cites this paper
• Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5‐year follow‐up of 150 patients

  2009cites this paper
• Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT‐C trial

  2009cites this paper
• Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

  2009cites this paper
• Critical review of clinical trials of bone marrow stem cells in liver disease.

  2008cites this paper
• Long-term Clinical Outcome of Treatment for Chronic Hepatitis C

  2008cites this paper
• Hepatology may have problems with putative surrogate outcome measures.

  2007cites this paper
• Baseline findings from the third collaborative injection drug users study/drug users intervention trial (CIDUS III/DUIT).

  2007cites this paper
• Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications

  2007cites this paper
• Hepatitis C Virus Infection—Pathobiology and Implications for New Therapeutic Options

  2007cites this paper
• Interferon-alpha improves bone resorption and osteopenia in patients with chronic hepatitis C.

  2006cites this paper
• [Treatment options for chronic hepatitis C virus infection].

  2006cites this paper
• Probability of liver cancer and survival in HCV‐related or alcoholic‐decompensated cirrhosis. A study of 377 patients

  2006cites this paper
• Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C

  2006cites this paper
• Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α‐2a (40 kDa) plus ribavirin: Impact on health‐related quality of life

  2006cites this paper
• Interferon-α improves bone resorption and osteopenia in patients with chronic hepatitis C

  2006cites this paper
• From Trials to a Real Hospital Setting: Effectiveness of Pegylated Interferon-α-2b/Ribavirin Combination Therapy for Naïve Chronic Hepatitis C Patients

  2006cites this paper
• Lower incidence of hepatic failure than hepatocellular carcinoma in Japanese patients with chronic Hepatitis C

  2005influential citation
• Genotypic Variability of Hepatitis Viruses Associated With Chronic Infection and the Development of Hepatocellular Carcinoma

  2005cites this paper
• Management of chronic hepatitis C

  2005cites this paper
• Global epidemiology of hepatitis C virus infection.

  2005cites this paper
• Long-term evolution of liver histopathology in patients with chronic hepatitis C and sustained response.

  2005cites this paper
• Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis

  2005cites this paper
• Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

  2005cites this paper
• Efficacy of prolonged treatment following combination with ribavirin and interferon for chronic hepatitis type C: A pilot study.

  2005cites this paper
• Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response

  2004cites this paper
• Hepatitis C Infection with History of Tuberculosis in Japan: No Association with Progression of Liver Fibrosis

  2004cites this paper
• Favorable Outcome of Patients with C-Viral Liver Disease Treated with Interferon

  2004cites this paper
• Comment traiter une première poussée d’ascite ?

  2004cites this paper
• Management of chronic hepatitis C virus infection: a new era of disease control

  2004cites this paper
• Efficacy of interferon therapy for aged patients with chronic hepatitis C

  2004cites this paper
• Viral hepatitis in 2003

  2004cites this paper
• Effects of Interferon Treatment Response on Liver Complications of Chronic Hepatitis C: 9-year Follow-Up Study

  2004cites this paper
• Management of hepatitis C.

  2004cites this paper
• Short‐term interferon‐alfa therapy for acute hepatitis C: A randomized controlled trial

  2004cites this paper
• [How to treat a first episode of ascites?].

  2004cites this paper
• Factors contributing to ribavirin‐induced anemia

  2004cites this paper
• Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy

  2004cites this paper
• When to treat patients with chronic hepatitis C

  2004cites this paper
• Comment traiter une ascite ? Comment traiter une première poussée d ’ ascite ?

  2004cites this paper
• Current Treatment for chronic hepatitis C

  2004cites this paper
• Can interferon prolong life?

  2003cites this paper
• Interferon Improves Long-Term Prognosis in Patients with Chronic HCV Infection

  2003cites this paper
• Efeito da resposta ao tratamento antiviral na ocorrência de carcinoma hepatocelular em pacientes com cirrose pelo vírus c

  2003cites this paper
• E1 therapeutic vaccination for chronic hepatitis C: All that glitters is not gold

  2003cites this paper